|
Session 1:
Crystallization of Complex Pharmaceutical Compound
|
Peptide crystallisation
Prof. Jerry Heng, Imperial College, UK
|
Vepdegestrant: Development of a Scalable Crystallization Process of a PROTAC Molecule
Dr. Noalle Fellah, Pfizer, USA
|
Learnings from Solid Form Development of Complex HCV Drugs
Dr. Shuang Chen, AbbVie, USA
|
Developing and optimizing a quench-crystallization operation in drug substance manufacturing
Mr. James D. Fostinis, Amgen
|
|
Session 2:
Particle Engineering to Address Formulation Challenge
|
Crystallization as a Purification Process: Visualizing Impurity Retention and its Effects on Crystal Properties
Prof. Gerard Capellades, Rowan University
|
Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin
Dr. Jeremy M. Merritt , Eli Lilly & Co.
|
Process Development and Robust Control of Physical Attributes of an Amorphous Drug Substance
Dr. Dimitrios Zarkadas, Merck & Co.
|
Addressing poor solubility and oiling-out tendencies of drug substances
Dr. Lotfi Derdour , GlaxoSmithKline
|
|
Session 3:
Computational Applications for Controlled Crystallization
|
Fast-tracking Pharmaceutical Process Optimization with Small Data and Machine Learning
Dr. Daniela Blanco, Sunthetics
|
Crystal structure prediction for realistic pharmaceutical targets with AIMNet2 neural network potential
Prof. Olexandr Isayev, Carnegie Mellon University
|
Solid Form Design and Selection Utilizing Combined Experimental and Computational Techniques
Dr. Rajni Miglani Bhardwaj, Pfizer
|
Computer-aided solid form design: Current challenges, future opportunities
Prof. Susan M. Reutzel-Edens, SuRE Pharma Consulting
|
